Canada markets close in 3 hours 23 minutes
  • S&P/TSX

    20,342.06
    +54.26 (+0.27%)
     
  • S&P 500

    4,407.76
    +20.60 (+0.47%)
     
  • DOW

    34,996.35
    +158.19 (+0.45%)
     
  • CAD/USD

    0.7971
    -0.0027 (-0.33%)
     
  • CRUDE OIL

    70.67
    -0.59 (-0.83%)
     
  • BTC-CAD

    47,976.79
    -2,354.32 (-4.68%)
     
  • CMC Crypto 200

    931.78
    -11.66 (-1.24%)
     
  • GOLD FUTURES

    1,813.10
    -9.10 (-0.50%)
     
  • RUSSELL 2000

    2,212.91
    -2.59 (-0.12%)
     
  • 10-Yr Bond

    1.1720
    -0.0020 (-0.17%)
     
  • NASDAQ

    14,718.58
    +37.51 (+0.26%)
     
  • VOLATILITY

    18.54
    -0.92 (-4.73%)
     
  • FTSE

    7,105.72
    +24.00 (+0.34%)
     
  • NIKKEI 225

    27,641.83
    -139.19 (-0.50%)
     
  • CAD/EUR

    0.6714
    -0.0017 (-0.25%)
     

Celldex to Present at the Jefferies 2021 Virtual Healthcare Conference

·1 min read

HAMPTON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:30 p.m. ET.

A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 30 days following the event.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Senior Director, Investor Relations & Corporate Communications
(484) 788-8560
ptill@celldex.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting